Five things for pharma marketers to know: Tuesday, April 4, 2017
1. Mylan is facing a class action lawsuit that claims it overcharged patients for its anaphylaxis injector, EpiPen. The complaint alleges that Mylan violated state consumer protection laws by increasing the list price of the drug in order to give a higher share of sales to pharmacy benefit managers. (WSJ)
2. More than 20% of patients were misdiagnosed by their primary-care providers, according to a new study published the Journal of Evaluation in Clinical Practice. Researchers said the study highlights the inherent difficulty of diagnosis. (WaPo)
3. Mallinckrodt Pharmaceuticals agreed to pay the Drug Enforcement Administration $35 million to settle a probe investigating the distribution of its drugs. Mallinckrodt sells several painkillers, including Exalgo, Xartemis, and Roxicodone. (AP)
4. Astellas plans to acquire Ogeda, a Belgian drugmaker, following positive Phase-II data for an experimental menopause drug. The deal is worth up to $860 million. (Endpts)
5. Sanofi will pay the Department of Justice $19.8 million over an accounting error that lead it to overcharge the Department of Veteran Affairs between 2002 and 2011. (TheStreet)
Correction: An earlier version of this article misstated that the DEA's probe of Mallinckodt was for marketing. It was for distribution.